Review Article

Drosophila as a Potential Model for Ocular Tumors

Daimark Bennett^a Ekaterina Lyulcheva^{a, b} Neville Cobbe^a

^aInstitute of Integrative Biology, University of Liverpool, Liverpool, and ^bNorth Western Deanery, Salford Royal NHS Foundation Trust, Salford, UK

Key Words

Ocular oncology · Retinoblastoma · Uveal melanoma · *Drosophila* · Cancer model · Ocular cancer

Abstract

Drosophila has made many contributions to our understanding of cancer genes and mechanisms that have subsequently been validated in mammals. Despite anatomical differences between fly and human eyes, flies offer a tractable genetic model in which to dissect the functional importance of genetic lesions found to be affected in human ocular tumors. Here, we discuss different approaches for using *Drosophila* as a model for ocular cancer and how studies on ocular cancer genes in flies have begun to reveal potential strategies for therapeutic intervention. We also discuss recent developments in the use of *Drosophila* for drug discovery, which is coming to the fore as *Drosophila* models are becoming tailored to study tumor types found in the clinic.

© 2015 S. Karger AG, Basel

Why Use *Drosophila* as a Cancer Model?

By combining a century of genetic research resulting in a vast array of powerful genetic tools with modern cutting-edge technologies, *Drosophila* offers unparalleled opportunities to elucidate complex interactions between genes, cells and tissues [1, 2]. In recent years, *Drosophila* has been increasingly utilized as a model organism for cancer research after work in cancer cell lines had failed to reliably predict clinical relevance [3] and expensive mammalian models had struggled to provide a sufficiently sophisticated panel of genetic tools to fully capture the intricacy of tumorigenesis and metastasis. Although flies do not normally develop cancer because of their limited life span, many biological processes related to tumorigenesis

Daimark Bennett
Institute of Integrative Biology
University of Liverpool
Crown Street, Liverpool L69 7ZB (UK)
E-Mail daimark@liv.ac.uk

and cancer progression are well conserved in flies, and the disruption or ectopic activation of cancer-related genes can lead to the development of several classic hallmarks of cancer, including genome instability, metabolic reprogramming, evasion of apoptosis, sustained proliferation, resisting cell death and invasive cell migration [4, 5]. Furthermore, studies in flies have yielded important conceptual insights into epithelial cancer development and progression, including cell competition, apoptosis-induced compensatory proliferation and oncogenic cooperation [6].

One of the key advantages of *Drosophila* is its relatively streamlined genome, which facilitates the conduct of large-scale genetic screens with comparative ease. The low level of redundancy means that hits are likely to provide insight into the gene function, while the high level of homology to ~75% of human disease-causing genes [7] means that *Drosophila* screens are often directly applicable to higher organisms, including humans. Indeed, such screens have identified many important and conserved cellular regulators that were later shown to be involved in tumor formation in humans, such as Notch (N), Hedgehog (Hh) and Salvador/Warts/Hippo [8]. Since nearly all of the genes implicated in the growth control from studies of human cancer are conserved in *Drosophila*, candidate genes identified in human cancers can be extensively studied in flies, where genes can be manipulated with unparalleled precision and the in vivo setting additionally enables studies to assess the role of the micro-environment in tumor development and progression. Furthermore, *Drosophila* has shown potential as a screening model for novel therapeutic compounds, putting it at the translational interface between basic science and clinical medicine [8].

How good a model is the *Drosophila* eye for ocular tumors? As with all cancer models, there is always the question of how closely the model replicates the specific cancer type. Obvious anatomical differences between fly eyes and human eyes, with the structure of the photosensitive organ (compound insect eye versus the camera-style human eye) being the most notable, naturally limit how directly applicable findings in flies are to specific cell types in human eyes. Importantly, however, numerous genes involved in eye specification (e.g. *ey*, *toy*, *so* and *eya*) or in orchestrating the proper temporal and spatial organization of the eye components (e.g. *hh* and *ato*) are highly conserved in both flies and humans, and mutations result in retinal defects in both systems alike [9, 10]. *Drosophila* therefore offers a valuable genetic model in which to test interactions between cancer-related genes found to drive the development or progression of ocular tumors in humans.

Using the *Drosophila* Toolkit for Gene Discovery

Targeted overexpression or knockdown of any number of candidate genes is the bread-and-butter methodology utilized by fly geneticists (fig. 1a, b). The targeting techniques are becoming increasingly sophisticated, allowing genes to be misexpressed or knocked down in individual cells, clones of cells or specific tissues at different developmental time points and in different genetic backgrounds [11]. Manipulated cells can be readily labeled with a fluorescent protein, facilitating the analysis of the resultant phenotypes and cellular behaviors such as invasion and metastasis. Clonal analysis (fig. 1b) enables the study of the effects of multiple genetic alterations on populations of cells alongside phenotypically normal cells, recapitulating the events that take place during the growth and spread of cancerous cells in otherwise healthy tissues and organs in humans. It can also inform us about the role of tumor microenvironments. Sophisticated functional and complementation analyses can be carried out by combining different knockdown or expression constructs, which may be wild type or carry site-directed mutations of interest, with loss-of-function mutants within the same clonal patch.

Although such analyses can be carried out in a multitude of tissues, the *Drosophila* eye in particular has attracted much attention because genetic manipulations in this nonessential tissue tend to give rise to viable animals displaying visible and easy-to-score phenotypes. For example, the *Drosophila* eye has been used to identify pathways required for neoplastic transformation and metastasis in situ. One widely used model utilizes constitutively active Ras (Ras^{V12}) targeted to the developing eye in larvae. Ras^{V12} expression results in benign hyperplastic tumors that can be readily used to screen for genetic modifiers required for neoplasia and metastasis (fig. 1c). Studies in this system revealed the critical role of the cell polarity genes *scrib*, *lgl* and *dlg* in inhibiting tumor progression and metastasis [12, 13]. In particular, cells lacking *scrib* and concurrently expressing Ras^{V12} acquire invasive properties, and affected animals display distant secondary foci of tumorous growths. Genetic

Color version available online

1

(For legend see next page.)

analysis has further revealed the role of JNK activation, interclonal cooperation, extracellular matrix remodeling and the immune system for invasion and metastasis in this model (reviewed in Miles et al. [14]). Fundamental insights, such as these, into our understanding of epithelial cancer biology are likely to help guide studies of cancer in more advanced model organisms, including mammals. Indeed, mislocalization or downregulation of Dlg1, Scrib and Lgl1 have been correlated with early dysplastic stages of ocular adenocarcinoma in a mouse model [15].

The strength of *Drosophila* as an organism of choice for sophisticated genetic screens is further demonstrated by the identification and characterization of a remarkable gain-of-function mutant, *eyeful*, which was identified as a modifier of the eye overgrowth phenotype resulting from the overexpression of the Notch ligand encoded by *Delta* [16]. As well as displaying further eye enlargement, flies overexpressing *Delta* and concurrently carrying the *eyeful* mutation in the developing eye were found to have ectopic eye tissue throughout the body that originated from the dissemination of transformed cells from the developing eye. Intriguingly, further analysis revealed that the *eyeful* mutation resulted in the hypermethylation and inhibition of the tumor suppressor gene Retinoblastoma, demonstrating the significance of epigenetic modifications in neoplastic transformation and metastasis [16].

Investigating Ocular Cancer Genes in *Drosophila*

Drosophila is increasingly being used to generate specific alterations in conserved tumor suppressors or oncogenes in an attempt to replicate pathway-specific modes of tumorigenesis or metastasis found in different tumor types. These models can then be interrogated, e.g. using forward genetic screens, to devise ways to specifically affect the growth, survival or dissemination of resulting tumor cells. This approach may be of particular relevance to relatively rare cancer types that require tissue-specific or less commonly utilized oncogenic drivers that may be overlooked in forward genetic screens. In the following section, we discuss the insights that studies on the retinoblastoma tumor suppressor gene in flies have

Fig. 1. Utilizing the genetic toolkit in *Drosophila* for cancer studies. The GAL4/UAS expression system [65] (**a**) and the FLP/FRT system [66] (**b**) are two of the most commonly used tools to manipulate gene function in *Drosophila*. **a** The GAL4/UAS bipartite expression system allows flexible overexpression or knockdown of a gene of interest in different tissues or stages of development. Flies carrying one of many available GAL4 lines are crossed to flies carrying the gene of interest under the control of the UAS element. Binding of GAL4 to the UAS element in the progeny drives the expression in the pattern of the GAL4 line. Publicly available genome-wide RNA interference and overexpression UAS libraries [67, 68] have broadened the utility of this approach. Temperature-sensitive alleles of GAL80, a repressor of GAL4-mediated gene expression, can also be employed in this system for further temporal control of expression (not shown). **b** The FLP/FRT system can be used to generate clones of mutant cells in otherwise normal tissues. Expression of the *Flp* gene, for example under the control of a heat shock (*hs*) promoter, results in recombination between two *FRT* (Flp recombination target) sites on sister chromatids. One of the resulting daughter cells is consequently homozygous mutant for the gene of interest and is negatively labeled by the absence of GFP, whereas GFP expression labels both the parental cell and the other daughter cell, which are heterozygous and homozygous wild type for the gene of interest, respectively. This system can be coupled with GAL80 to positively label mutant cells lacking the repressor (not shown). **c** Combining the approaches outlined in **a** and **b**, it is possible to generate clones of cells ectopically expressing an activated oncogene whilst simultaneously harboring additional mutations that affect the properties of the resulting tumors (see Pagliarini and Xu [12] for details). For instance, cells overexpressing *Ras*^{V12} in the developing eye lead to localized non-invasive tumors. The presence of additional metastasis-inducing factors (e.g. gene X) drives the formation of secondary tumors visualized by the presence of GFP in other parts of the larva.

made towards potential treatments of the corresponding disease and explore the potential for developing models of uveal melanoma, the most common malignant tumor of the eye in adults, based on what is known about the underlying genetic drivers.

RB1 and Retinoblastoma

Retinoblastoma, the most common malignant tumor of the eye in children, is an aggressive neoplasm that develops from immature cells of the retina following biallelic loss of the RB1 gene [17, 18]. Like RB1, the *Drosophila* ortholog *rbf1* is best known for the regulation of the G1/S transition via the repression of E2F-dependent transcription [19]. Mutations in *rbf1* have only a modest effect on eye development and are not sufficient to drive tumor formation in *Drosophila*. By investigating context-dependent effects, it has been found that both *rbf1* and RB1 cooperate with the hippo tumor suppressor pathway in cell proliferation control and cell specification. Cells that are double mutant for *rbf1* and *hippo* dedifferentiate from a neuronal state and become uncommitted eye-specific cells with an increased potential to contribute to tumor growth [20]. It was subsequently shown that Yki, a transcriptional coactivator that is inactivated by Hippo signaling in flies, requires the transcription factor E2F to transcribe genes necessary to bypass exit from the cell cycle [21]. Similarly, the Hippo pathway and the RB1-mediated regulation of the G1/S transition in human cells are required for RB1-mediated repression of E2F target genes and consequent RB1-induced inhibition of cell proliferation [22].

A further constraint on tumor development is that *rbf1* mutant cells are sensitized to undergo apoptosis, which can be triggered for example by signaling from the cellular micro-environment [23] or by further genetic insults to the defective cells [24]. Using clonal genetic screens in the fly eye, loss-of-function mutations in the Tsc2 tumor suppressor [24] or a highly conserved peptidyl prolyl isomerase [25] were independently found to eliminate cells lacking *rbf1* but allow wild-type cells to survive. It was subsequently found that inactivation of human Tsc2 in cancer cells inhibited the growth of RB1 mutant cells and induced cell death under stress conditions [24], suggesting potential therapeutic strategies for treating cancers in which RB1 has been inactivated. Importantly, the confirmation of synthetic lethality in a cancer cell line clearly illustrates the power of *Drosophila* as a discovery tool.

Uveal Melanoma Cancer Genes

Whereas retinoblastoma is largely considered to be a single-gene disease, in uveal melanoma, several genetic and epigenetic lesions have been variously associated with tumor development or progression [26]. As illustrated above, multigenic models of tumorigenesis can be readily generated in the fly. Activated oncogenes can be readily expressed ectopically; however, modeling the effects of the loss of human tumor suppressor genes is limited by the requirement for the presence and expression of the relevant homologs in the fly. Importantly, almost all of the genes implicated in uveal melanoma are conserved in *Drosophila* (table 1), including ubiquitous oncogenes or tumor suppressors, such as IGFR1, B-RAF and PTEN, which play conserved roles in growth and proliferation control in all metazoans, as well as highly conserved tissue-specific factors, such as G protein α_q subunits GNAQ/GNA11 [27], which in *Drosophila* is required for the termination of phototransduction and prevents retinal degeneration [28]. The insult most closely associated with metastasis of uveal melanoma cells is somatic loss-of-function mutations in the BRCA1-associated protein 1 (*BAP1*) tumor suppressor, which have been reported in nearly 50% of primary uveal melanomas and 84% of metastasizing tumors [29, 30]. Both human *BAP1* and the *Drosophila* counterpart encoded by *calypso* act as the catalytic subunits of a Polycomb repressive deubiquitinase (PR-DUB) complex, which remove ubiquitin from histone H2A in nucleosomes to repress Hox and other genes [31]. This is particularly interesting given the well-established role of certain Polycomb Group (PcG) genes as tumor suppressors in the *Drosophila* eye, including Sex combs extra (Sce, an E3 ligase

Table 1. Uveal melanoma cancer genes and their counterparts in *Drosophila*

Associated human gene	Contribution to uveal melanoma	Frequency	<i>Drosophila</i> orthologue	Effect in <i>Drosophila</i>
Tumor suppressors				
<i>BAP1</i>	Mutational inactivation of BAP1 implicated in uveal melanoma metastasis [29, 30]	Inactivating somatic mutations in up to 84% of tumors	<i>calypso</i>	Control of cellular differentiation
<i>PTEN</i>	Submicroscopic deletions lead to loss of PTEN expression in uveal melanoma [39]	Mutations in the PTEN coding region identified in 11.4% of tumors; up to 76.3% of tumors with loss of heterozygosity of at least one PTEN marker	<i>PTEN</i>	PTEN mutants exhibit eye overgrowth, whereas PTEN overexpression inhibits cell proliferation and promotes cell death during eye development [40]
<i>p53</i>	Altered expression in uveal melanomas following plaque radiotherapy, with elevated p53 levels [41]	Strong p53 staining observed in 50% of eyes containing posterior uveal melanomas	<i>p53</i>	Ectopic expression in the eye disc causes cell death and leads to a rough eye phenotype [42]
<i>SF3B1</i>	Mutations in a distinct molecular subset of uveal melanomas [43]	Mutations in 18.6% of tumors	<i>CG2807-PA</i>	No phenotypic data
Potential diagnostic markers				
<i>MC1R</i>	Highly overexpressed in uveal melanoma [44]	Detected in 95% of tested melanoma tissues	No clear orthologue identified	
<i>SSR2</i> , <i>SSR3</i> and <i>SSR5</i>	Expressed in human uveal melanomas; better prognosis for patients with high levels of SSR2 in melanoma tissue [45]	Immunohistochemical staining positive for SSR2 in all uveal melanomas, whilst SSR3 was found in 29% and SSR5 in 58% of tumors	<i>AICR2</i>	AICR2 is closest to SSR2; no data for the effect on the eye
Proto-oncogenes				
<i>GNAQ</i> and <i>GNA11</i>	Constitutively active in uveal melanoma [27, 46]	Activating mutations affecting GNA11 in up to 49% of primary uveal melanomas and in 45% of uveal melanomas for GNAQ	<i>Gaq</i>	Loss leads to retinal degeneration [28]
<i>MYC</i>	Amplification of the c-myc oncogene detected in 43% of uveal melanomas [47]	70% of uveal melanomas with extra copies of c-myc	<i>diminutive</i>	Myc overexpression in the eye induces both growth and apoptosis, yielding large rough eyes [48]
<i>CCND1</i>	Cyclin D1 protein expression was observed in 65% of uveal melanomas [49] and is associated with more aggressive disease [50]	Expression observed in 65% of uveal melanomas	<i>Cyclin D</i>	Clonal expression of CycD-Cdk4 promotes cellular hypertrophy in post-mitotic cells of differentiating eyes [51]
<i>DDEF1</i>	DDEF1 is commonly overexpressed in high-grade uveal melanomas [52]	Elevated expression in high-grade (class 2) tumors, corresponding to 50% of uveal melanoma patients more likely to die of metastatic disease	<i>Asap1</i>	No phenotypic data are available
<i>NBS1</i>	High expression of Nbs1 associated with increased metastatic death in uveal melanoma patients [53]	Elevated expression in high-grade (class 2) tumors, corresponding to 50% of uveal melanoma patients more likely to die of metastatic disease	<i>nbs</i>	Null mutant flies die as pharate adults with rough eyes [54]
<i>IGF1R</i>	High expression associated with metastases of primary uveal melanomas [55]	High IGF1R expression in 50% of patients who died following metastasis but in only 25% of patients who survived 15 years	<i>InR</i>	Increased activity leads to overgrowth of the eye, reduced activity leads to reduced eye growth [56]
<i>Jag2</i>	May promote Notch activity, growth and metastasis in uveal melanoma [57]	Elevated expression in high-grade (class 2) tumors, corresponding to 50% of uveal melanoma patients more likely to die of metastatic disease	<i>Serrate</i>	Loss of function has no discernible effect on eye development [58] but is required for cell survival with Lobe during early eye development [59]
<i>B-RAF</i>	Low prevalence of mutations but frequent downstream activation of the MAPK pathway associated with uveal melanoma [60–62]	Rare; mutations detected in 14.3% of uveal melanoma cell lines and primary specimens	<i>phl</i>	Rough eye phenotype due to loss of photoreceptor cells [63]; photoreceptors fail to differentiate in mutant somatic clones of the larval eye disc [64]

MC1R = Melanocortin 1 receptor; *AICR2* = allatostatin C receptor 1; *Gaq* = G protein α q subunit; *IGF1R* = insulin-like growth factor 1 receptor; *InR* = insulin-like receptor; *phl* = pole hole.

required for H2A monoubiquitylation), which operates synergistically with the PR-DUB complex to transcriptionally repress a subset of PcG target genes [32, 33]. Armed with the knowledge of some of the genetic events driving uveal melanoma [26] and given the conservation of the affected genes in flies, it will be possible to begin to devise *Drosophila* models with which to help determine the key players in uveal melanoma development and progression.

Fig. 2. Strategies for testing the ability of chemical inhibitors to suppress the effects of RET^{MEN2} overexpression in *Drosophila*. **a** Eye-specific expression: ectopic overexpression of RET^{MEN2} under the control of the GMR promoter results in a fully penetrant rough eye phenotype in adults (red lines). Flies fed with vandetanib (ZD6474) strongly rescue defective eye development (blue line) [35]. **b** Expression in developing epithelia (wing, eye and leg) and other tissues: ectopic expression of UAS-RET^{MEN2} under the control of *ptc-GAL4* results in lethality early in development (red line). This assay was used to screen a library of polypharmacological compounds capable of restoring viability (blue line). Further chemical refinement of initial hits identified a compound, AD80, with optimal efficacy and toxicity compared to analogs [37]. Colors refer to the online version only.

Future Perspectives

Future efforts to develop *Drosophila* strains that are specifically modeled on human data will ensure that insights can be more quickly taken back into mammals or cancer cell lines for validation and ultimate translation into clinical practice. With respect to translational potential, *Drosophila* has begun to emerge as a time and cost-efficient model for whole-animal drug testing to find suitable compounds capable of targeting cancer signaling in a multicellular context. A particularly successful example of the utility of *Drosophila* for drug development has come from studies of activated forms of the RET (rearranged during transfection) proto-oncogene, which are associated with several types of cancers, including type 2 multiple endocrine neoplasia (MEN2), an inherited condition that can result in the development of cancers such as medullary thyroid carcinoma (fig. 2). Ectopic expression of oncogenic RET (RET^{MEN2}) in the developing fly eye results in overproliferation, cell fate defects and cell death, leading to the formation of visibly 'rough' adult eyes [34]. Using this simple assay, flies were fed ZD6474 (vandetanib) to test whether this compound, which had previously been shown to inhibit RET, was capable of modulating RET^{MEN2} function in the whole organism when administered orally [35]. Notably, ZD6474 suppressed the RET^{MEN2}-mediated phenotypes at doses much lower than those required to cause toxicity to the animal. Following validation in flies, this compound subsequently passed clinical trials for the use in treating medullary thyroid carcinoma [36] and became the first drug to be approved by the FDA for the treatment of late-stage medullary thyroid cancer in adult patients who might be considered ineligible for surgery due to metastasis. This success has recently prompted further efforts to better understand the pathways responsible for drug efficacy and dose-limiting toxicity in the *Drosophila* RET^{MEN2} model as well as to develop new compounds with improved therapeutic

indices [37] (fig. 2b). Semi-automated methods for high-throughput screening are also being trialed to screen chemical compounds in larvae. A recent screen for suppressors of *Ras*^{V12} *scrib*^{-/-} tumor overgrowth in the developing eye identified clinically active drugs with known activity against human tumor cells that are similarly effective in flies [38]. These studies illustrate how models of cancer involving multiple genetic alterations in flies can serve as a starting point for pharmacological interrogation and how *Drosophila* can provide an important function in preselecting the most useful compounds prior to testing in more expensive mammalian models.

Conclusion

There is a long tradition of using *Drosophila* to identify universal regulators of basic cellular processes such as proliferation, differentiation and death. As more genetic data from clinical samples become available, *Drosophila* models offer the potential to recapitulate the properties of ocular tumors with increasing accuracy and therefore applicability. Aside from providing valuable mechanistic insight, tailored cancer models are increasingly being seen to have promise in drug discovery efforts, where they can help to bridge the gap from bench to bedside.

Acknowledgements

D.B. is supported by grants from CRUK and NWCR. E.L. is an Academic Clinical Fellow in Clinical Genetics. N.C. is supported by the NWCR.

References

- 1 Matthews KA, Kaufman TC, Gelbart WM: Research resources for *Drosophila*: the expanding universe. *Nat Rev Genet* 2005;6:179–193.
- 2 Venken KJ, Bellen HJ: Emerging technologies for gene manipulation in *Drosophila melanogaster*. *Nat Rev Genet* 2005;6:167–178.
- 3 Gillet JP, Varma S, Gottesman MM: The clinical relevance of cancer cell lines. *J Natl Cancer Inst* 2012;105:452–458.
- 4 Hanahan D, Weinberg RA: The hallmarks of cancer. *Cell* 2000;100:57–70.
- 5 Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. *Cell* 2011;144:646–674.
- 6 Vidal M, Cagan RL: *Drosophila* models for cancer research. *Curr Opin Genet Dev* 2006;16:10–16.
- 7 Reiter LT, Potocki L, Chien S, Gribskov M, Bier E: A systematic analysis of human disease-associated gene sequences in *Drosophila melanogaster*. *Genome Res* 2001;11:1114–1125.
- 8 Gonzalez C: *Drosophila melanogaster*: a model and a tool to investigate malignancy and identify new therapeutics. *Nat Rev Cancer* 2013;13:172–183.
- 9 Jarman AP: Developmental genetics: vertebrates and insects see eye to eye. *Curr Biol* 2000;10:R857–R859.
- 10 Kumar JP: Signalling pathways in *Drosophila* and vertebrate retinal development. *Nat Rev Genet* 2001;2:846–857.
- 11 Venken KJ, Bellen HJ: Genome-wide manipulations of *Drosophila melanogaster* with transposons, Flp recombinase, and PhiC31 integrase. *Methods Mol Biol* 2012;859:203–228.
- 12 Pagliarini RA, Xu T: A genetic screen in *Drosophila* for metastatic behavior. *Science* 2003;302:1227–1231.
- 13 Brumby AM, Richardson HE: scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in *Drosophila*. *EMBO J* 2003;22:5769–5779.
- 14 Miles WO, Dyson NJ, Walker JA: Modeling tumor invasion and metastasis in *Drosophila*. *Dis Model Mech* 2011;4:753–761.
- 15 Vieira V, de la Houssaye G, Lacassagne E, Dufier JL, Jais JP, Beermann F, Menasche M, Abitbol M: Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer. *Mol Vis* 2008;14:2390–2403.
- 16 Ferres-Marco D, Gutierrez-Garcia I, Vallejo DM, Bolivar J, Gutierrez-Avino FJ, Dominguez M: Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. *Nature* 2006;439:430–436.

- 17 Lohmann DR, Brandt B, Hopping W, Passarge E, Horsthemke B: The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. *Am J Hum Genet* 1996;58:940–949.
- 18 Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, Shurtleff S, Mullighan C, Pounds S, Mukatira S, Gupta P, Neale G, Zhao D, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Naeve C, Dyson NJ, Mardis ER, Bahrami A, Ellison D, Wilson RK, Downing JR, Dyer MA: A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature* 2012;481:329–334.
- 19 Du W, Vidal M, Xie JE, Dyson N: RBF, a novel RB-related gene that regulates E2F activity and interacts with cyclin E in *Drosophila*. *Genes Dev* 1996;10:1206–1218.
- 20 Nicolay BN, Bayarmagnai B, Moon NS, Benevolenskaya EV, Frolov MV: Combined inactivation of pRB and hippo pathways induces dedifferentiation in the *Drosophila* retina. *PLoS Genet* 2010;6:e1000918.
- 21 Nicolay BN, Bayarmagnai B, Islam AB, Lopez-Bigas N, Frolov MV: Cooperation between dE2F1 and Yki/Sd defines a distinct transcriptional program necessary to bypass cell cycle exit. *Genes Dev* 2011;25:323–335.
- 22 Tschoep K, Conery AR, Litovchick L, Decaprio JA, Settleman J, Harlow E, Dyson N: A kinase shRNA screen links LATS2 and the pRB tumor suppressor. *Genes Dev* 2011;25:814–830.
- 23 Moon NS, Di Stefano L, Dyson N: A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. *Mol Cell Biol* 2006;26:7601–7615.
- 24 Li B, Gordon GM, Du CH, Xu J, Du W: Specific killing of Rb mutant cancer cells by inactivating TSC2. *Cancer Cell* 2010;17:469–480.
- 25 Edgar KA, Belvin M, Parks AL, Whittaker K, Mahoney MB, Nicoll M, Park CC, Winter CG, Chen F, Lickteig K, Ahmad F, Esengil H, Lorenzi MV, Norton A, Rupnow BA, Shayesteh L, Tabios M, Young LM, Carroll PM, Koczynski C, Plowman GD, Friedman LS, Francis-Lang HL: Synthetic lethality of retinoblastoma mutant cells in the *Drosophila* eye by mutation of a novel peptidyl prolyl isomerase gene. *Genetics* 2005;170:161–171.
- 26 Coupland SE, Lake SL, Zeschnigk M, Damato BE: Molecular pathology of uveal melanoma. *Eye (Lond)* 2013;27:230–242.
- 27 Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenaus AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC: Mutations in GNA11 in uveal melanoma. *N Engl J Med* 2010;363:2191–2199.
- 28 Hu W, Wan D, Yu X, Cao J, Guo P, Li HS, Han J: Protein Gq modulates termination of phototransduction and prevents retinal degeneration. *J Biol Chem* 2012;287:13911–13918.
- 29 Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH: Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. *J Med Genet* 2011;48:856–859.
- 30 Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM: Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science* 2010;330:1410–1413.
- 31 Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW, Muller J: Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. *Nature* 2010;465:243–247.
- 32 Gutierrez L, Oktaba K, Scheuermann JC, Gambetta MC, Ly-Hartig N, Muller J: The role of the histone H2A ubiquitinase Sce in Polycomb repression. *Development* 2012;139:117–127.
- 33 Classen AK, Bunker BD, Harvey KF, Vaccari T, Bilder D: A tumor suppressor activity of *Drosophila* Polycomb genes mediated by JAK-STAT signaling. *Nat Genet* 2009;41:1150–1155.
- 34 Read RD, Goodfellow PJ, Mardis ER, Novak N, Armstrong JR, Cagan RL: A *Drosophila* model of multiple endocrine neoplasia type 2. *Genetics* 2005;171:1057–1081.
- 35 Vidal M, Wells S, Ryan A, Cagan R: ZD6474 suppresses oncogenic RET isoforms in a *Drosophila* model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. *Cancer Res* 2005;65:3538–3541.
- 36 Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol* 2012;30:134–141.
- 37 Dar AC, Das TK, Shokat KM, Cagan RL: Chemical genetic discovery of targets and anti-targets for cancer pharmacology. *Nature* 2012;486:80–84.
- 38 Willoughby LF, Schlosser T, Manning SA, Parisot JP, Street IP, Richardson HE, Humbert PO, Brumby AM: An in vivo large-scale chemical screening platform using *Drosophila* for anti-cancer drug discovery. *Dis Model Mech* 2013;6:521–529.
- 39 Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C: High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. *J Clin Oncol* 2006;24:288–295.
- 40 Huang H, Potter CJ, Tao W, Li DM, Brogiolo W, Hafen E, Sun H, Xu T: PTEN affects cell size, cell proliferation and apoptosis during *Drosophila* eye development. *Development* 1999;126:5365–5372.
- 41 Brantley MA Jr, Worley L, Harbour JW: Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy. *Am J Ophthalmol* 2002;133:242–248.
- 42 Yamaguchi M, Hirose F, Inoue YH, Shiraki M, Hayashi Y, Nishi Y, Matsukage A: Ectopic expression of human p53 inhibits entry into S phase and induces apoptosis in the *Drosophila* eye imaginal disc. *Oncogene* 1999;18:6767–6775.
- 43 Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM: Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. *Nat Genet* 2013;45:133–135.

- 44 Lopez MN, Pereda C, Ramirez M, Mendoza-Naranjo A, Serrano A, Ferreira A, Poblete R, Kalergis AM, Kiessling R, Salazar-Onfray F: Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. *Invest Ophthalmol Vis Sci* 2007;48:1219–1227.
- 45 Ardjomand N, Ardjomand N, Schaffler G, Radner H, El-Shabrawi Y: Expression of somatostatin receptors in uveal melanomas. *Invest Ophthalmol Vis Sci* 2003;44:980–987.
- 46 Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW: Oncogenic mutations in GNAQ occur early in uveal melanoma. *Invest Ophthalmol Vis Sci* 2008;49:5230–5234.
- 47 Parrella P, Caballero OL, Sidransky D, Merbs SL: Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. *Invest Ophthalmol Vis Sci* 2001;42:1679–1684.
- 48 Steiger D, Furrer M, Schwinkendorf D, Gallant P: Max-independent functions of Myc in *Drosophila melanogaster*. *Nat Genet* 2008;40:1084–1091.
- 49 Coupland SE, Bechrakis N, Schuler A, Anagnostopoulos I, Hummel M, Bornfeld N, Stein H: Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. *Br J Ophthalmol* 1998;82:961–970.
- 50 Coupland SE, Anastassiou G, Stang A, Schilling H, Anagnostopoulos I, Bornfeld N, Stein H: The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. *J Pathol* 2000;191:120–126.
- 51 Datar SA, Jacobs HW, de la Cruz AF, Lehner CF, Edgar BA: The *Drosophila* cyclin D-Cdk4 complex promotes cellular growth. *EMBO J* 2000;19:4543–4554.
- 52 Ehlers JP, Worley L, Onken MD, Harbour JW: DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. *Clin Cancer Res* 2005;11:3609–3613.
- 53 Ehlers JP, Harbour JW: NBS1 expression as a prognostic marker in uveal melanoma. *Clin Cancer Res* 2005;11:1849–1853.
- 54 Oikemus SR, Queiroz-Machado J, Lai K, McGinnis N, Sunkel C, Brodsky MH: Epigenetic telomere protection by *Drosophila* DNA damage response pathways. *PLoS Genet* 2006;2:e71.
- 55 All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O: Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. *Invest Ophthalmol Vis Sci* 2002;43:1–8.
- 56 Brogiolo W, Stocker H, Ikeya T, Rintelen F, Fernandez R, Hafen E: An evolutionarily conserved function of the *Drosophila* insulin receptor and insulin-like peptides in growth control. *Curr Biol* 2001;11:213–221.
- 57 Asnaghi L, Handa JT, Merbs SL, Harbour JW, Eberhart CG: A role for Jag2 in promoting uveal melanoma dissemination and growth. *Invest Ophthalmol Vis Sci* 2013;54:295–306.
- 58 Baker NE, Yu SY: Proneural function of neurogenic genes in the developing *Drosophila* eye. *Curr Biol* 1997;7:122–132.
- 59 Singh A, Shi X, Choi KW: Lobe and Serrate are required for cell survival during early eye development in *Drosophila*. *Development* 2006;133:4771–4781.
- 60 Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F: Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. *J Biol Chem* 2003;278:42409–42418.
- 61 Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, Van der Velden PA: Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. *Invest Ophthalmol Vis Sci* 2008;49:23–27.
- 62 Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, Pavey S, van der Velden P, Out C, Jager MJ, Hayward NK, Gruis NA: Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. *Br J Cancer* 2005;92:2032–2038.
- 63 Lim YM, Tsuda L, Inoue YH, Irie K, Adachi-Yamada T, Hata M, Nishi Y, Matsumoto K, Nishida Y: Dominant mutations of *Drosophila* MAP kinase kinase and their activities in *Drosophila* and yeast MAP kinase cascades. *Genetics* 1997;146:263–273.
- 64 Yang L, Baker NE: Cell cycle withdrawal, progression, and cell survival regulation by EGFR and its effectors in the differentiating *Drosophila* eye. *Dev Cell* 2003;4:359–369.
- 65 Elliott DA, Brand AH: The GAL4 system: a versatile system for the expression of genes. *Methods Mol Biol* 2008;420:79–95.
- 66 Theodosiou NA, Xu T: Use of FLP/FRT system to study *Drosophila* development. *Methods* 1998;14:355–365.
- 67 Bischof J, Bjorklund M, Furger E, Schertel C, Taipale J, Basler K: A versatile platform for creating a comprehensive UAS-ORFeome library in *Drosophila*. *Development* 2013;140:2434–2442.
- 68 Dietzl G, Chen D, Schnorrrer F, Su KC, Barinova Y, Fellner M, Gasser B, Kinsey K, Oppel S, Scheiblaue S, Couto A, Marra V, Keleman K, Dickson BJ: A genome-wide transgenic RNAi library for conditional gene inactivation in *Drosophila*. *Nature* 2007;448:151–156.